References of "Beckers, Albert"
     in
Bookmark and Share    
Peer Reviewed
See detailAspects genetiques du male 46, XX.
Marquet, F.; Beckers, Albert ULg; Verloes, Alain ULg

in Revue Médicale de Liège (1998), 53(12), 738-740

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism ... [more ▼]

The XX males represent a proportion of 1/25 of all patients suffering of the Klinefelter syndrome. From a clinical and endocrinological point of view, they exhibit a hypogonadotropic hypogonadism. Isolated cases are rare and familial forms are exceptional. The XX males may be divided in 3 subgroups: 46, XX males with the SRY gene; 46, XX males without the SRY gene and XX/XY mosaics. [less ▲]

Detailed reference viewed: 56 (5 ULg)
Full Text
See detailLes hypertensions artérielles d'origine endocrinienne.
Beckers, Albert ULg

in Tempo Médical (1998), 196

Les hypertensions artérielles d'origine endocrinienne représentent environ 3 à 5 % des hypertensions artérielles, parmi lesquelles les formes les plus sévères. Lors du diagnostic, une importance ... [more ▼]

Les hypertensions artérielles d'origine endocrinienne représentent environ 3 à 5 % des hypertensions artérielles, parmi lesquelles les formes les plus sévères. Lors du diagnostic, une importance particulière sera accordée à une sémiologie évocatrice. Une cause endocrinienne sera également activement recherchée dans les cas de mauvaises réponses au traitement classique de l'hypertension artérielle. [less ▲]

Detailed reference viewed: 21 (0 ULg)
Peer Reviewed
See detailLe cas clinique du mois Un homme a caryotype 46,XX.
Marquet, F.; Verloes, Alain ULg; Beckers, Albert ULg

in Revue Médicale de Liège (1998), 53(9), 515-517

The XX males represent a rare expression of the Klinefelter syndrome associated with hypergonadotropic hypogonadism. Generally the patients are of small stature with normal secondary sexual male features ... [more ▼]

The XX males represent a rare expression of the Klinefelter syndrome associated with hypergonadotropic hypogonadism. Generally the patients are of small stature with normal secondary sexual male features but with small testes and constant sterility. The plasma concentrations of FSH and LH are very high in accordance with the decrease of the testicular function. From the genetic point of view, the XX males may be divided in 3 groups: 1) in 80% of cases, the XX males bear the SRY gene and exhibit a XY translation during the paternal meiosis with the presence of the SRY gene on one of the X chromosomes as a marker of the male differentiation; 2) in 10% of cases, the males are (SRY-)XX; the abnormal development is then due to other genes than the TDF, which, when mutated, can induce sexual male differentiation. The remaining 10% of cases are due to chromosomal mosaicism with more XX than XY. [less ▲]

Detailed reference viewed: 182 (4 ULg)
Peer Reviewed
See detailComment j'explore ... les pathologies thyroidiennes par cytoponction echoguidee.
Meunier, Paul ULg; Lebrun, Yves ULg; Quatresooz, Pascale ULg et al

in Revue Médicale de Liège (1998), 53(12), 784-787

From a retrospective study of 259 files, the authors stress the value of US-guided thyroid cytoponction and its essential role in case of thyroid cancer suspicion. This very specific and inexpensive ... [more ▼]

From a retrospective study of 259 files, the authors stress the value of US-guided thyroid cytoponction and its essential role in case of thyroid cancer suspicion. This very specific and inexpensive method fits perfectly into the other exploration techniques. It is the deciding factor in the thyroid nodule differential diagnostic and therapeutic planning. [less ▲]

Detailed reference viewed: 68 (5 ULg)
See detailLes mutations NEM-1 dans les familles belges
Beckers, Albert ULg

Scientific conference (1997, November)

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailL'hyperaldostéronisme primaire. Mise au point et traitement raisonnés.
Baudoin, Béatrice ULg; Hamoir, Etienne ULg; Defechereux, Thierry et al

in Revue Française d'Endocrinologie Clinique, Nutrition, et Métabolisme (La) (1997), 38(6), 555-568

Depuis la découverte par Jérôme Conn, en 1954, de l'adénome sécréteur d'aldostérone (ou aldostéronome), neuf variétés ou associations particulières d'hyperaldostéronisme primaire ont été décrites. La ... [more ▼]

Depuis la découverte par Jérôme Conn, en 1954, de l'adénome sécréteur d'aldostérone (ou aldostéronome), neuf variétés ou associations particulières d'hyperaldostéronisme primaire ont été décrites. La manifestation principale de ce désordre endocrinien est l'hypertension artérielle, réfractaire aux thérapeutiques habituelles. Cependant, certains types d'hyperaldostéronisme sont sensibles à la chirurgie qui éradique cette hypertension et ses conséquences. Il importe donc de distinguer ces différentes variétés grâce aux moyens d'investigations actuellement à notre disposition afin d'appliquer le traitement le plus judicieux dans chaque cas. [less ▲]

Detailed reference viewed: 132 (2 ULg)
See detailLes hypertensions artérielles d'origine endocrinienne
Beckers, Albert ULg

Scientific conference (1997, October 17)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailTwo years of replacement therapy in adults with growth hormone deficiency.
Verhelst, J.; Abs, R.; Vandeweghe, M. et al

in Clinical Endocrinology (1997), 47(4), 485-494

OBJECTIVES: Although several studies have shown beneficial short-term effects of recombinant human growth hormone (rhGH) therapy in adult GH deficient (GHD) patients, few data are available on large ... [more ▼]

OBJECTIVES: Although several studies have shown beneficial short-term effects of recombinant human growth hormone (rhGH) therapy in adult GH deficient (GHD) patients, few data are available on large groups of patients treated for more than one year. In addition, the optimal dose of rhGH for each patient and the baseline parameters that predict which patients will benefit most from therapy or will have adverse events are not entirely elucidated. DESIGN: 148 adult GHD patients were enrolled in a multicentre 2-year rhGH replacement study which was placebo controlled for the first six months. rhGH (Genotropin/Genotonorm Pharmacia & Upjohn) was given in a dose of 0.25 IU/kg/week sc (1.5 IU/m2/day). MEASUREMENTS: Every 3-6 months body composition was measured using body impedance analysis and general well being was assessed using the Nottingham Health Profile (NHP) and social self-reporting questionnaire. At the same time patients had a full clinical examination and blood was sampled for glucose, HbA1c, IGF-1, creatinine, full blood count, thyroid hormones and liver function tests. RESULTS: With rhGH therapy IGF-1 levels increased from -2.00 +/- 2.60 SDS to 1.47 +/- 2.6 SDS after six months (P < 0.001), continued to rise despite no change in dose to 1.84 +/- 2.8 SDS after one year and remained constant thereafter (1.98 +/- 2.4 after 2 years). 56% of patients ultimately attained supranormal IGF-1 levels (+2 SD), 22% had levels below the mean, of which 9% were below -2 SD. Within 3 months lean body mass (LBM) increased by +5.09% (P < 0.001), total body water (TBW) by +5.40% (P < 0.001), while body fat (BF) dropped by -10.89% (P < 0.001) and waist circumference by -1.42% (P < 0.004). These effects were maintained during the first year of therapy, but the effect was attenuated after 24 months: LBM, +3.91% (P < 0.001); TBW, +3.28%, P < 0.001, BF, -6.42% (P < 0.001) and waist -2.22% (P < 0.009). Individual differences in response were large and could not be predicted by any of the baseline parameters, except for a better response in males. Treatment resulted in a large and progressive improvement on the NHP scale, especially energy, emotions and sleep, but a similar change was also found in patients during placebo treatment. With rhGH the number of full days of sick leave/6 months decreased from 12.17 +/- 3.90 days (SEM) to 7.15 +/- 3.50 days after six months (P = 0.009), 2.93 +/- 1.55 days after 12 months (P = 0.01), 0.39 +/- 0.17 days after 18 months (P < 0.001) and 3.3 +/- 2.51 days after 24 months (P = 0.026). Similarly, the hospitalization rate went down from 14.9 to 7% after 6 months and remained at this level thereafter (P = 0.12). About one third of patients on rhGH experienced fluid-related adverse events, most often within the first 3 months. They usually disappeared spontaneously or responded well to dose reduction. Cumulative dropout rates were 29% after 1 year and 38% after two years. Two thirds of these patients stopped treatment because of insufficient subjective improvement. Neither drop-outs nor fluid retention could not be predicted by any of the baseline parameters. CONCLUSIONS: We confirmed in a large group of patients the beneficial effects of rhGH therapy on body composition, metabolic parameters and general well-being and found a consistent drop in number of sick days and hospitalization rate. These effects were maintained during two years of therapy, except for an attenuation in body composition changes after 24 months. The high incidence of fluid-related adverse events suggests that it may be better to start with lower doses of rhGH and to increase the dose more slowly over a number of weeks. The finding of suboptimal high or low IGF-1 levels in many patients reinforces guidelines not to give rhGH in a weight-dependent dose but to titrate it individually for each patient. [less ▲]

Detailed reference viewed: 29 (1 ULg)
See detailTreatment options for recurrent pituitary tumours
Beckers, Albert ULg

Scientific conference (1997, September)

Detailed reference viewed: 7 (0 ULg)
See detailThe Medical Treatment of hyperprolactinemia
Beckers, Albert ULg

Scientific conference (1997, June)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailProcessus expansifs non-adénomateux intra-sellaires
Rohmer, V.; Chanson, Philippe; Dupas, B. et al

in Annales d'Endocrinologie (1997), 58(1), 11-19

More than thirty types of tumors in the sellar region can mimic pituitary adenoma on, magnetic resonance imaging. When they exist, clinical manifestations are not necessarily highly contributive to ... [more ▼]

More than thirty types of tumors in the sellar region can mimic pituitary adenoma on, magnetic resonance imaging. When they exist, clinical manifestations are not necessarily highly contributive to diagnosis. Headache, visual impairment, signs of antepituitary insufficiency or possible dysmenorrhea with galactorrhea attributed to hyperprolactinemia due to compression of the dopaminergic axis are not specific and may be misleading. Clinical signs of diabetes insipidis and polyphagia are however suggestive of non-pituitary tumors. Consequently, high-resolution imaging (MRI) and sometimes particular diagnostic circumstances (post partum for hypophysitis for example, or breast cancer for metastasis) orient the diagnosis. More rarely tumor enlargement, for example in certain germ cell tumors, provides a clue. [less ▲]

Detailed reference viewed: 105 (3 ULg)
Full Text
Peer Reviewed
See detailExpression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy.
Caron, Philippe; Buscail, Louis; Beckers, Albert ULg et al

in Journal of Clinical Endocrinology and Metabolism (1997), 82(11), 3771-3776

In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma ... [more ▼]

In pregnancy, the human placenta GH acts as a growth-promoting hormone and appears to be the main stimulator of insulin-like growth factor I (IGF-I) secretion. In a woman with a TSH-secreting macroadenoma, successful treatment with the somatostatin analog octreotide was conducted during the first month and the second half of pregnancy without side-effects on placental and fetal development. As observed in normal pregnancy, both serum placental GH and IGF-I levels increased throughout pregnancy and dropped sharply after delivery. In placental membranes from both treated and healthy untreated patients, we demonstrated the presence of high affinity binding sites for somatostatin-14 (Kd, 4.6 and 5.3 nmol/L; binding capacity, 1.53 and 1.35 pmol/mg protein, respectively). These receptors displayed low affinity for octreotide (IC50, 1.2-2 mumol/L), suggesting the presence of SST1 and/or SST4 receptors. We found that messenger ribonucleic acids of these two subtypes were expressed in both human placental tissue and purified human cytotrophoblast cells. Finally, the SST1-selective analog, des-AA1,2,5[D-Trp8,IAmp9]S-14 had low affinity for placental somatostatin receptors. These results argue in favor of the presence of the SST4 subtype in human placenta. At the doses administered, octreotide did not bind to placental somatostatin receptors. Our results may explain the absence of changes in both human placental GH and IGF-I concentrations that we observed during octreotide treatment. [less ▲]

Detailed reference viewed: 36 (3 ULg)
See detailEvaluation of us-guided percutaneous fine needle aspiration biopsyin thyroïd nodules
Meunier, Paul ULg; Collignon, J.; Thiry, Albert ULg et al

in International Congress of Head and neck Radiology - Abstract book (1997)

Detailed reference viewed: 23 (0 ULg)
Full Text
See detailAn epidemiological survey of 783 patients who underwent pituitary surgery in a single Centre over a 25-year periods
Beckers, Albert ULg; Petrossians, Patrick ULg; Stevenaert, Achille ULg

in 24th International Symposium on GH and growth factors in Endocrinology and Metabolism - Abstract book (1997)

Detailed reference viewed: 5 (0 ULg)
See detailSomatostatini SSTR2 and dopamine D2 receptors gene expression in Growth hormone-producing pituitary adenomas
Ronci, N.; Tabarin, A.; Beckers, Albert ULg et al

in 78th Endocrine Society Annual Meeting - Abstract book (1997)

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailExpression des récepteurs somatostatinergiques SSTR2 et dopaminergiques D2 dans les adénomes somatotropes
Tabarin, A.; Ronci, N.; Carrié, F. et al

in Annales d'Endocrinologie (1997), 58(2),

Detailed reference viewed: 20 (0 ULg)
See detailCellular distribution of NSP in normal pituitary and in pituitary adenomas. Comparison with pituitary hormone expression.
Dukers, N.; Senden, N.; Timmer, E. et al

in 4th Euregional oncology meeting - abstract book (1997)

Detailed reference viewed: 4 (1 ULg)
See detailClinical and genetic aspects of MEN1 and related diseases : a 3 year experience based on the French-Belgian Study group on MEN1
Calender, A.; Murat, A.; Carpentier, B. et al

in 6th International Workshop on Multiple Endocrine Neoplasia and Von Hippel-Lindau Disease (1997)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailSomatostatin SSTR2 and Dopamine D2 receptors gene expression in Growth Hormone-producing pituitary adenomas
Ronci, N.; Tabarin, A.; Beckers, Albert ULg et al

in Annales d'Endocrinologie (1997), 58(1),

Detailed reference viewed: 6 (0 ULg)